SLG-200
Bacterial Keratitis / Infectious Keratitis
Pre-clinicalActive
Key Facts
About Selagine
Selagine is a private, preclinical-stage biotech developing innovative biologic and antibody-based therapies for ocular surface diseases. Its lead asset, SLG-100, is a clinical-stage biologic eye drop for Dry Eye Disease (DED) with a novel mechanism targeting cytokines and autoantibodies, while SLG-200 is a novel ophthalmic antibiotic for bacterial keratitis. The company is based in Chicago, operates from UIC's incubator, and is led by its founder, Dr. Sandeep Jain, supported by a small team of scientific and business advisors.
View full company profile